Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing sales forecast for tardive dyskinesia (TD) drug Ingrezza commanded much of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback